NFKB1 and rheumatoid arthritis: Nuclear factor kappa B ligand (RANKL) was associated with the activation of NF-kB, which could lead to bone erosion and bone destruction, and the use of RANKL inhibitors could inhibit bone loss in RA by interfering with osteoclasts (28).